{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/52272"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/52272","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Development of mouse models of multisystemic histiocytosis-like disease with bone involvement","abstract":"Histiocytosis features the aberrant functions of macrophages, osteoclasts, and other cells of hematopoietic origin. It has an extensive range of phenotypic presentations involving single organ or multiple organs. The bone phenotype of histiocytosis, the most prominent in juvenile cases, is in most cases aggressive and lethal. Current treatments available are broad and have limited effectiveness. The BRAF gene is an oncogene involved in the mitogen activated protein kinase (MAPK) pathway. A point mutation in the BRAF gene resulting in replacement of valine (V) to glutamine (E) at the aminoacidic position 600 results in constitutive activity generally common in cancers and Langerhans cell histiocytosis. Exploration of more specific treatment methods for histiocytosis targets the BRAF V600E mutation. Here we work on developing and testing new mouse models that express BrafV600E mutations. Further analysis of the fluorescent labeling efficiency of tamoxifen inducible mouse model will be completed before proceeding to inducing histiocytosis-like disease with bone involvement in mice.","abstract_html":"Histiocytosis features the aberrant functions of macrophages, osteoclasts, and other cells of hematopoietic origin. It has an extensive range of phenotypic presentations involving single organ or multiple organs. The bone phenotype of histiocytosis, the most prominent in juvenile cases, is in most cases aggressive and lethal. Current treatments available are broad and have limited effectiveness. The BRAF gene is an oncogene involved in the mitogen activated protein kinase (MAPK) pathway. A point mutation in the BRAF gene resulting in replacement of valine (V) to glutamine (E) at the aminoacidic position 600 results in constitutive activity generally common in cancers and Langerhans cell histiocytosis. Exploration of more specific treatment methods for histiocytosis targets the BRAF V600E mutation. Here we work on developing and testing new mouse models that express BrafV600E mutations. Further analysis of the fluorescent labeling efficiency of tamoxifen inducible mouse model will be completed before proceeding to inducing histiocytosis-like disease with bone involvement in mice.","abstract_has_math":false,"creators":["Deroly, Darah Rose-Merlie"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Bragdon, Beth"],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T20:24:45Z","subjects":["Medicine","Biology","Systematic biology","Bone","BRAF","Histiocytosis","Macrophages","Mouse model","Osteoclasts"],"languages":["en_US"],"rights":["Attribution 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by/4.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/52272","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/52272","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F52272","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bragdon, Beth"]},{"key":"dc:creator","label":"Author","values":["Deroly, Darah Rose-Merlie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-02-11T20:05:52Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-02-11T20:05:52Z"]},{"key":"dc:date.issued","label":"Date","values":["2025"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-02-10T23:02:30Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine","Biology","Systematic biology","Bone","BRAF","Histiocytosis","Macrophages","Mouse model","Osteoclasts"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/52272"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2025"]},{"key":"dc:description.abstract","label":"Abstract","values":["Histiocytosis features the aberrant functions of macrophages, osteoclasts, and other cells of hematopoietic origin. It has an extensive range of phenotypic presentations involving single organ or multiple organs. The bone phenotype of histiocytosis, the most prominent in juvenile cases, is in most cases aggressive and lethal. Current treatments available are broad and have limited effectiveness. The BRAF gene is an oncogene involved in the mitogen activated protein kinase (MAPK) pathway. A point mutation in the BRAF gene resulting in replacement of valine (V) to glutamine (E) at the aminoacidic position 600 results in constitutive activity generally common in cancers and Langerhans cell histiocytosis. Exploration of more specific treatment methods for histiocytosis targets the BRAF V600E mutation. Here we work on developing and testing new mouse models that express BrafV600E mutations. Further analysis of the fluorescent labeling efficiency of tamoxifen inducible mouse model will be completed before proceeding to inducing histiocytosis-like disease with bone involvement in mice."]},{"key":"dc:title","label":"Title","values":["Development of mouse models of multisystemic histiocytosis-like disease with bone involvement"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bragdon, Beth"],"dc:creator":["Deroly, Darah Rose-Merlie"],"dc:date.accessioned":["2026-02-11T20:05:52Z"],"dc:date.available":["2026-02-11T20:05:52Z"],"dc:date.issued":["2025"],"dc:date.updated":["2026-02-10T23:02:30Z"],"dc:description":["2025"],"dc:description.abstract":["Histiocytosis features the aberrant functions of macrophages, osteoclasts, and other cells of hematopoietic origin. It has an extensive range of phenotypic presentations involving single organ or multiple organs. The bone phenotype of histiocytosis, the most prominent in juvenile cases, is in most cases aggressive and lethal. Current treatments available are broad and have limited effectiveness. The BRAF gene is an oncogene involved in the mitogen activated protein kinase (MAPK) pathway. A point mutation in the BRAF gene resulting in replacement of valine (V) to glutamine (E) at the aminoacidic position 600 results in constitutive activity generally common in cancers and Langerhans cell histiocytosis. Exploration of more specific treatment methods for histiocytosis targets the BRAF V600E mutation. Here we work on developing and testing new mouse models that express BrafV600E mutations. Further analysis of the fluorescent labeling efficiency of tamoxifen inducible mouse model will be completed before proceeding to inducing histiocytosis-like disease with bone involvement in mice."],"dc:identifier.uri":["https://hdl.handle.net/2144/52272"],"dc:language.iso":["en_US"],"dc:rights":["Attribution 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by/4.0/"],"dc:subject":["Medicine","Biology","Systematic biology","Bone","BRAF","Histiocytosis","Macrophages","Mouse model","Osteoclasts"],"dc:title":["Development of mouse models of multisystemic histiocytosis-like disease with bone involvement"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:24:45Z"}